Wide Ranks

ENSC

Ensysce Biosciences, Inc.

0.5012

Top Statistics
Market Cap 9 M Forward PE -0.7371 Revenue Growth -62.90 %
Current Ratio 1.88 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue 3.54 Price To Sales Trailing12 Months 6.82
Profitability
Profit Margins 0.00 % Operating Margins -1075.62 %
Balance Sheet
Total Cash 1 M Total Cash Per Share 0.1230 Total Debt 454463
Total Debt To Equity 30.72 Current Ratio 1.88 Book Value Per Share -0.1030
All Measures
Short Ratio 12.00 % Message Board Id finmb_51791423 Shares Short Prior Month 180215
Return On Equity -4.28 City La Jolla Uuid bf708ef4-2980-393a-937c-06cb0bc6dda1
Previous Close 0.5480 First Trade Date Epoch Utc 1 B Book Value -0.1030
Beta 0.6390 Total Debt 454463 Volume 718494
Last Split Date 1 B Fifty Two Week Low 0.1410 Total Cash Per Share 0.1230
Total Revenue 1 M Shares Short Previous Month Date 1 B Target Median Price 6.80
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins -1075.62 %
Target Mean Price 6.80 Net Income To Common -11278438 Short Percent Of Float 0.4508
Implied Shares Outstanding 19 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 2 M Average Volume10days 2 M Total Cash 1 M
Next Fiscal Year End 1 B Revenue Per Share 0.2740 Held Percent Insiders 0.0117
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 0.5480 Target Low Price 5.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 0.4106 Open 0.5499 Free Cashflow -5387422
State CA Dividend Yield 0.00 % Return On Assets -1.32
Time Zone Short Name EST Trailing Eps -1.94 Day Low 0.4906
Address1 7946 Ivanhoe Avenue Shares Outstanding 19 M Price Hint 4
Target High Price 8.60 Website https://www.ensysce.com 52 Week Change -0.5605
Average Volume 26 M Forward Eps -0.9100 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 97.00 % Last Split Factor 1:12
Regular Market Day High 0.5500 Is_sp_500 False Profit Margins 0.00 %
Debt To Equity 30.72 Fifty Two Week High 2.06 Day High 0.5500
Shares Short 6 M Regular Market Open 0.5499 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 3.54 Revenue Growth -62.90 %
Shares Percent Shares Out 0.4261 Operating Cashflow -9782815 Currency USD
Time Zone Full Name America/New_York Market Cap 9 M Is_nasdaq_100 False
Zip 92037 Quote Type EQUITY Industry Biotechnology
Long Name Ensysce Biosciences, Inc. Regular Market Day Low 0.4906 Held Percent Institutions 0.2226
Current Price 0.5012 Address2 Suite 201 Financial Currency USD
Current Ratio 1.88 Industry Disp Biotechnology Number Of Analyst Opinions 2
Country United States Float Shares 6 M Two Hundred Day Average 0.5410
Enterprise Value 5 M Price To Sales Trailing12 Months 6.82 Forward PE -0.7371
Regular Market Volume 718494 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States.

It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.

The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis.

It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder.

The company was founded in 2003 and is based in La Jolla, California.